Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of GLPG0974 in Subjects With Ulcerative Colitis

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Ulcerative Colitis
Interventions
DRUG

GLPG0974

1 capsule in the morning and 1 capsule in the evening with food during 28 days

DRUG

Placebo

1 capsule in the morning and 1 capsule in the evening with food during 28 days

Trial Locations (16)

Unknown

Imelda, Bonheiden

UZ Gent, Ghent

AZ Groeninge, Kortrijk

UZ Leuven, Leuven

Hepato-Gastroenterologie HK, s.r.o., Hradec Králové

Fakulní nemocnice Olomouc, Olomouc

Homolka Hospitál, Prague

Nemocnice Slaný, Slaný

Krajská zdravotní a.s., Masarykova nemocnice v Ústí nad Labem T. Bati a.s., Ústí nad Labem

Krajská nemocnice Tomáše Bati - Zlin, Zlín

Nemocnice Znojmo, Znojmo

Latvijas Jūras Medicīnas Centrs, Riga

Rīgas slimnīca Bikor Holim, Riga

"SIA Gremošanas slimību centrs Gastro", Riga

Univerzitná nemocnica Bratislava, Bratislava

Fakultná Nemocnica Nitra, Nitra

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Galapagos NV

INDUSTRY

NCT01829321 - Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of GLPG0974 in Subjects With Ulcerative Colitis | Biotech Hunter | Biotech Hunter